Publicacions

Gestational phthalate exposure and lung function during childhood: A prospective population-based study

M. BASEA, A. CARSIN, A. ABELLAN, I. COBO, A. LERTXUNDI, N. MARIN, R. -BLASCO, J. IBARLUZEA, M. VRIJHEID, J. SUNYER, M. CASAS and J. GARCIA-AYMERICH
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.envpol.2022.119833 PMID:35931390

The potential effect of gestational exposure to phthalates on the lung function levels during childhood is unclear. Therefore, we examined this association at different ages (from 4 to 11 years) and over the whole childhood. Specifically, we measured 9 phthalate metabolites (MEP, MiBP, MnBP, MCMHP, MBzP, MEHHP, MEOHP, MECPP, MEHP) in the urine of 641 gestating women from the INMA study (Spain) and the forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and FEV1/FVC in their offspring at ages 4, 7, 9 and 11. We used linear regression and mixed linear regression with a random intercept for subject to assess the association between phthalates and lung function at each study visit and for the overall childhood, respectively. We also assessed the phthalate metabolites mixture effect on lung function using a Weighted Quantile Sum (WQS) regression. We observed that the phthalate metabolites gestational levels were consistently associated with lower FVC and FEV1 at all ages, both when assessed individually and jointly as a mixture, although most associations were not statistically significant. Of note, a 10% increase in MiBP was related to lower FVC (-0.02 (-0.04, 0)) and FEV1 z-scores (-0.02 (-0.04,-0.01) at age 4. Similar significant reductions in FVC were observed at ages 4 and 7 associated with an increase in MEP and MnBP, respectively, and for FEV1 at age 4 associated with an increase in MBzP. WQS regression consistently identified MBzP as an important contributor to the phthalate mixture effect. We can conclude that the gestational exposure to phthalates was associated with children’s lower FVC and FEV1, especially in early childhood, and in a statistically significant manner for MEP, MiBP, MBzP and MnBP. Given the ubiquity of phthalate exposure and its established endocrine disrupting effects in children, our findings support current regulations that limit phthalate exposure.

Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain

E. ROEL, B. RAVENTOS, E. BURN, A. PISTILLO, D. PRIETO-ALHAMBRA and T. DUARTE-SALLES
Aten Primaria.2022 Aug; 54(9):102437.doi:10.3201/eid2811.220614 PMID:36220130

Evidence on the impact of the COVID-19 vaccine roll-out on socioeconomic COVID-19-related inequalities is scarce. We analyzed associations between socio-economic deprivation index (SDI) and COVID-19 vac-cination, infection, and hospitalization before and after vaccine rollout in Catalonia, Spain. We conducted a population-based cohort study during September 2020- June 2021 that comprised 2,297,146 adults >40 years of age. We estimated odds ratio of nonvaccination and hazard ratios (HRs) of infection and hospitalization by SDI quintile relative to the least deprived quintile, Q1. Six months after rollout, vaccination coverage differed by SDI quintile in working-age (40-64 years) persons: 81% for Q1, 71% for Q5. Before rollout, we found a pattern of in-creased HR of infection and hospitalization with depriva-tion among working-age and retirement-age (>65 years) persons. After rollout, infection inequalities decreased in both age groups, whereas hospitalization inequalities decreased among retirement-age persons. Our findings suggest that mass vaccination reduced socioeconomic COVID-19-related inequalities.

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US br

X. LI, E. BURN, T. DUARTE-SALLES, C. YIN, C. REICH, A. DELMESTRI, K. VERHAMME, P. RIJNBEEK, M. SUCHARD, K. LI, M. MOSSEVELD, L. JOHN, M. MAYER, J. RAMIREZ-ANGUITA, C. COHET, V. STRAUSS and D. PRIETO-ALHAMBRA
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1136/bmj-2022-071594 PMID:36288813

  • Ans: 26/10/2022
  • FI: 105.7
  • Article

OBJECTIVE To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with use of adenovirus based covid-19 vaccines versus mRNA based covid-19 vaccines.DESIGN International network cohort study.SETTING Routinely collected health data from contributing datasets in France, Germany, the Netherlands, Spain, the UK, and the US.PARTICIPANTS Adults (age a18 years) registered at any contributing database and who received at least one dose of a covid-19 vaccine (ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), or Ad26.COV2.S (Janssen/Johnson & Johnson)), from December 2020 to mid-2021.MAIN OUTCOME MEASURES Thrombosis with thrombocytopenia syndrome or venous or arterial thromboembolic events within the 28 days after covid-19 vaccination. Incidence rate ratios were estimated after propensity scores matching and were calibrated using negative control outcomes. Estimates specific to the database were pooled by use of random effects meta-analyses.RESULTS Overall, 1 332 719 of 3 829 822 first dose ChAdOx1-S recipients were matched to 2 124 339 of 2 149 679 BNT162b2 recipients from Germany and the UK. Additionally, 762 517 of 772 678 people receiving Ad26.COV2.S were matched to 2 851 976 of 7 606 693 receiving BNT162b2 in Germany, Spain, and the US. All 628 164 Ad26.COV2.S recipients from the US were matched to 2 230 157 of 3 923 371 mRNA-1273 recipients. A total of 862 thrombocytopenia events were observed in the matched first dose ChAdOx1-S recipients from Germany and the UK, and 520 events after a first dose of BNT162b2. Comparing ChAdOx1-S with a first dose of BNT162b2 revealed an increased risk of thrombocytopenia (pooled calibrated incidence rate ratio 1.33 (95% confidence interval 1.18 to 1.50) and calibrated incidence rate difference of 1.18 (0.57 to 1.8) per 1000 person years). Additionally, a pooled calibrated incidence rate ratio of 2.26 (0.93 to 5.52) for venous thrombosis with thrombocytopenia syndrome was seen with Ad26.COV2.S compared with BNT162b2.CONCLUSIONS In this multinational study, a pooled 30% increased risk of thrombocytopenia after a first dose of the ChAdOx1-S vaccine was observed, as was a trend towards an increased risk of venous thrombosis with thrombocytopenia syndrome after Ad26.COV2.S compared with BNT162b2. Although rare, the observed risks after adenovirus based vaccines should be considered when planning further immunisation campaigns and future vaccine development.

Evaluating a novel approach to stimulate open science collaborations: a case series of “study-a-thon” events within the OHDSI and European IMI communities

N. HUGHES, P. RIJNBEEK, K. VAN BOCHOVE, T. DUARTE-SALLES, C. STEINBEISSER, D. VIZCAYA, D. PRIETO-ALHAMBRA and P. RYAN
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1093/jamiaopen/ooac100 PMID:36406796

Objective We introduce and review the concept of a study-a-thon as a catalyst for open science in medicine, utilizing harmonized real world, observation health data, tools, skills, and methods to conduct network studies, generating insights for those wishing to use study-a-thons for future research. Materials and Methods A series of historical study-a-thons since 2017 to present were reviewed for thematic insights as to the opportunity to accelerate the research method to conduct studies across therapeutic areas. Review of publications and experience of the authors generated insights to illustrate the conduct of study-a-thons, key learning, and direction for those wishing to conduct future such study-a-thons. Results A review of six study-a-thons have provided insights into their scientific impact, and 13 areas of insights for those wishing to conduct future study-a-thons. Defining aspects of the study-a-thon method for rapid, collaborative research through network studies reinforce the need to clear scientific rationale, tools, skills, and methods being collaboratively to conduct a focused study. Well-characterized preparatory, execution and postevent phases, coalescing skills, experience, data, clinical input (ensuring representative clinical context to the research query), and well-defined, logical steps in conducting research via the study-a-thon method are critical. Conclusions A study-a-thon is a focused multiday research event generating reliable evidence on a specific medical topic across different countries and health systems. In a study-a-thon, a multidisciplinary team collaborate to create an accelerated contribution to scientific evidence and clinical practice. It critically accelerates the research process, without inhibiting the quality of the research output and evidence generation, through a reproducible process.
Lay Summary The research process is generally time-consuming, requiring considerable efforts and resources and planning over an extended duration of time before its results, such as via publications. Meanwhile, patients, clinicians, and healthcare providers need evidence to support decision-making from individual treatment to populations and public health policy, and more quickly than we have been used to, to date. This article describes an approach to accelerating the research process, bringing together relevant research and clinical practitioners, whilst not undermining confidence in the research results. Within this article the research event, or study-a-thon, is described, using six examples since 2017, within an international research network, Observational Health Data Sciences and Informatics (OHDSI). These examples help illustrate the steps required to conduct a study-a-thon, the use of health data under the right conditions, and learning from this process for others to consider using study-a-thons to accelerate their own research process where relevant. For the authors and colleagues in the OHDSI network, the open nature of conducting research via study-a-thons can also ensure full transparency of the process for all involved, as well as being able to reproduce results more readily, a key principle in good scientific conduct.

Endometriosis prevalence and incidence trends in a large population-based study in Catalonia (Spain) from 2009 to 2018

L. MEDINA-PERUCHA, A. PISTILLO, B. RAVENTOS, C. JACQUES-AVINO, J. MUNROS-FELIU, C. MARTINEZ-BUENO, C. VALLS-LLOBET, F. CARMONA, T. LOPEZ-JIMENEZ, G. PUJOLAR-DIAZ, E. ARCAS, A. BERENGUERA and T. DUARTE-SALLES
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1177/17455057221130566 PMID:36281527

Objective: Endometriosis greatly impacts women’s health and quality of life. However, research on the prevalence and incidence of endometriosis remains inconclusive. This study assesses time trends in the prevalence and incidence of endometriosis diagnoses in Catalonia (Spain) from 2009 to 2018, considering differences by age and socioeconomic status.
Methods: Population-based cohort study using data from the Information System for Research in Primary Care (SIDIAP) database. Data were included from over 2.4 million women aged 15-55 years between 1 January 2006 and 31 December 2018.
Results: A total of 2,337,717 women were selected as the incident population; 0.7% had an endometriosis diagnosis. Median (interquartile range) age at diagnosis was 37 (32-43) years. Most women were European (92.3%) and lived in urban areas (73.6%). Overall prevalence of endometriosis consistently increased during the 2009-2018 period, and it was 1.24% in 2018. Trends were the highest for women with less socioeconomic deprivation and for the 35-44 years age group. Median incidence rates were 94.9 (92.6-102.9) per 100,000 women-years, being the highest in women aged 35-44 years throughout the whole study period. Overall, incidence increased between 2015 and 2017, and plateaued or decreased in 2018. Incidence rates in women from the most deprived and rural areas were lower, although incidence time trends by socioeconomic status were unclear.
Conclusion: Healthcare services and public health strategies need to be strengthened to ensure timely endometriosis diagnosis and treatment. Special attention should be given to the most affected populations and the social inequities of health.

Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis

C. YANG, R. WILLIAMS, J. SWERDEL, J. ALMEIDA, E. BROUWER, E. BURN, L. CARMONA, K. CHATZIDIONYSIOU, T. DUARTE-SALLES, W. FAKHOURI, A. HOTTGENROTH, M. JANI, R. KOLDE, J. KORS, L. KULLAMAA, J. LANE, K. MARINIER, A. MICHEL, H. STEWART, A. PRATS-URIBE, S. REISBERG, A. SENA, C. TORRE, K. VERHAMME, D. VIZCAYA, J. WEAVER, P. RYAN, D. PRIETO-ALHAMBRA and P. RIJNBEEK
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.semarthrit.2022.152050 PMID:35728447

Background: Identification of rheumatoid arthritis (RA) patients at high risk of adverse health outcomes remains a major challenge. We aimed to develop and validate prediction models for a variety of adverse health outcomes in RA patients initiating first-line methotrexate (MTX) monotherapy.
Methods: Data from 15 claims and electronic health record databases across 9 countries were used. Models were developed and internally validated on Optum (R) De-identified Clinformatics (R) Data Mart Database using Ll -regularized logistic regression to estimate the risk of adverse health outcomes within 3 months (leukopenia, pancytopenia, infection), 2 years (myocardial infarction (MI) and stroke), and 5 years (cancers [colorectal, breast, uterine] after treatment initiation. Candidate predictors included demographic variables and past medical history. Models were externally validated on all other databases. Performance was assessed using the area under the receiver operator characteristic curve (AUC) and calibration plots.
Findings: Models were developed and internally validated on 21,547 RA patients and externally validated on 131,928 RA patients. Models for serious infection (AUC: internal 0.74, external ranging from 0.62 to 0.83), MI (AUC: internal 0.76, external ranging from 0.56 to 0.82), and stroke (AUC: internal 0.77, external ranging from 0.63 to 0.95), showed good discrimination and adequate calibration. Models for the other outcomes showed modest internal discrimination (AUC < 0.65) and were not externally validated. Interpretation: We developed and validated prediction models for a variety of adverse health outcomes in RA patients initiating first-line MTX monotherapy. Final models for serious infection, MI, and stroke demonstrated good performance across multiple databases and can be studied for clinical use.

Residential Proximity to Urban Play Spaces and Childhood Overweight and Obesity in Barcelona, Spain: A Population-Based Longitudinal Study

N. SANCHEZ-VALDIVIA, C. PEREZ-DEL-PULGAR, J. DE BONT, I. ANGUELOVSKI, A. LOPEZ-GAY, A. PISTILLO, M. TRIGUERO-MAS and T. DUARTE-SALLES
Aten Primaria.2022 Aug; 54(9):102437.doi:10.3390/ijerph192013676 PMID:36294256

  • Ans: 01/10/2022
  • FI: 4.614
  • Article

Findings on the relationship between play spaces and childhood overweight and obesity are mixed and scarce. This study aimed to investigate the associations between residential proximity to play spaces and the risk of childhood overweight or obesity and potential effect modifiers. This longitudinal study included children living in the city of Barcelona identified in an electronic primary healthcare record database between 2011 and 2018 (N = 75,608). Overweight and obesity were defined according to the WHO standards and we used 300 m network buffers to assess residential proximity to play spaces. We calculated the risk of developing overweight or obesity using Cox proportional hazard models. A share of 29.4% of the study population developed overweight or obesity, but we did not find consistent associations between play space indicators and overweight or obesity. We did not find any consistent sign of effect modification by sex, and only some indications of the modifying role of area socioeconomic status and level of exposure. Although it is not possible to draw clear conclusions from our study, we call for cities to continue increasing and improving urban play spaces with an equitable, healthy, and child-friendly perspective.

Multimorbidity worsened anxiety and depression symptoms during the COVID-19 pandemic in Brazil.

Castro-de-Araujo LFS, Rodrigues EDS, Machado DB, Henriques CMP, Verotti MP, Gonçalves AQ, Duarte-Salles T, Kanaan RA, Barreto ML, Lewis G and Barbosa JR
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1016/j.jad.2022.07.005 PMID:35810830

Multimorbidity is a global health issue impacting the quality of life of all ages. Multimorbidity with a mental disorder is little studied and is likely to have been affected by the COVID-19 pandemic. We used a survey of 14,007 respondents living in Brazil to investigate whether people who already had at least one chronic medical condition had more depression and anxiety symptoms during social distancing in 2020. Generalized linear models and structural equation modelling were used to estimate the effects. A 19 % and 15 % increase in depressive symptoms were found in females and males, respectively, for each unit of increase in the observed value of reported chronic disease. Older subjects presented fewer symptoms of depression and anxiety. There was a 16 % increase in anxiety symptoms in females for each unit increase in the reported chronic disease variable and a 14 % increase in males. Younger subjects were more affected by anxiety symptoms in a dose-response fashion. High income was significantly related to fewer depressive and anxiety symptoms in both males and females. Physical activity was significantly associated with fewer anxiety and depression symptoms. Structural equation modelling confirmed these results and provided further insight into the hypothesised paths.

International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients.

Nishimura A, Xie J, Kostka K, Duarte-Salles T, Fernández Bertolín S, Aragón M, Blacketer C, Shoaibi A, DuVall SL, Lynch K, Matheny ME, Falconer T, Morales DR, Conover MM, Chan You S, Pratt N, Weaver J, Sena AG, Schuemie MJ, Reps J, Reich C, Rijnbeek PR, Ryan PB, Hripcsak G, Prieto-Alhambra D and Suchard MA
Aten Primaria.2022 Aug; 54(9):102437.doi:10.3389/fphar.2022.945592 PMID:36188566

Purpose: Alpha-1 blockers, often used to treat benign prostatic hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storm release. The proposed treatment based on this hypothesis currently lacks support from reliable real-world evidence, however. We leverage an international network of large-scale healthcare databases to generate comprehensive evidence in a transparent and reproducible manner. Methods: In this international cohort study, we deployed electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We assessed association between alpha-1 blocker use and risks of three COVID-19 outcomes-diagnosis, hospitalization, and hospitalization requiring intensive services-using a prevalent-user active-comparator design. We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including large-scale propensity score matching/stratification and negative control calibration. We pooled database-specific estimates through random effects meta-analysis. Results: Our study overall included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH medications. We observed no significant difference in their risks for any of the COVID-19 outcomes, with our meta-analytic HR estimates being 1.02 (95% CI: 0.92-1.13) for diagnosis, 1.00 (95% CI: 0.89-1.13) for hospitalization, and 1.15 (95% CI: 0.71-1.88) for hospitalization requiring intensive services. Conclusion: We found no evidence of the hypothesized reduction in risks of the COVID-19 outcomes from the prevalent-use of alpha-1 blockers-further research is needed to identify effective therapies for this novel disease.

Trends in the incidence of asthma in children and adolescents in Catalonia, 2010-2021: a large population-based cohort study

A. ABELLAN, B. RAVENTOS, E. BURN, A. PISTILLO and T. DUARTE-SALLES
Aten Primaria.2022 Aug; 54(9):102437.doi:10.1183/13993003.congress-2022.2416 PMID:

Patronat

Col·laboradors

Acreditacions